Toru Naganuma

Showing 1-9 of 9 articles

Silent Valsalva thrombus between the native Valsalva and balloon-expandable transcatheter heart valve: multicentre Japanese registry analysis

Tsunaki T, Yamamoto M, Shimura T, Kagase A, Naganuma T, Higashimori A, Araki M, Yamanaka F, Mizutani K, Watanabe Y, Otsuka T, Yanagisawa R, Hayashida K

November 15, 2019 | 10.4244/EIJ-D-19-00370

Coronary interventions

Predilation, sizing and post-dilation scoring in patients undergoing everolimus-eluting bioresorbable scaffold implantation for prediction of cardiac adverse events: development and internal validation of the PSP score

Ortega-Paz L, Capodanno D, Gori T, Nef H, Latib A, Caramanno G, Di Mario C, Naber C, Lesiak M, Capranzano P, Wiebe J, Mehilli J, Araszkiewicz A, Pyxaras S, Mattesini A, Geraci S, Naganuma T, Colombo A, Münzel T, Sabate M, Tamburino C, Brugaletta S

April 20, 2017 | 10.4244/EIJ-D-16-00974

Coronary interventions

Clinical outcomes of a real-world cohort following bioresorbable vascular scaffold implantation utilising an optimised implantation strategy

Tanaka A, Latib A, Kawamoto H, Jabbour R, Sato K, Miyazaki T, Naganuma T, Mangieri A, Pagnesi M, Montalto C, Chieffo A, Carlino M, Montorfano M, Colombo A

February 20, 2017 | 10.4244/EIJ-D-16-00247

Coronary interventions

Procedural outcomes of patients with calcified lesions treated with bioresorbable vascular scaffolds

Panoulas V, Miyazaki T, Sato K, Naganuma T, Sticchi A, Kawamoto H, Figini F, Chieffo A, Carlino M, Montorfano M, Latib A, Colombo A

March 18, 2016 | 10.4244/EIJY15M03_11

Coronary interventions

Drug-eluting balloon versus second-generation drug-eluting stent for the treatment of restenotic lesions involving coronary bifurcations

Naganuma T, Latib A, Costopoulos C, Oreglia J, Testa L, De Marco F, Candreva A, Chieffo A, Naim C, Montorfano M, Bedogni F, Colombo A

January 20, 2016 | 10.4244/EIJY14M11_01

How should I treat multiple coronary aneurysms with severe stenoses?

Warisawa T, Naganuma T, Nakamura S

November 20, 2015 | 10.4244/EIJV11I7A171

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry

Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C

February 20, 2015 | 10.4244/EIJY14M07_11

Percutaneous intervention of calcific coronary lesions

Costopoulos C, Naganuma T, Colombo A

March 3, 2014

Tools and Techniques Clinical: Percutaneous intervention of calcific coronary lesions

Costopoulos C, Naganuma T, Colombo A

January 20, 2014 | 10.4244/EIJV9I9A188

1

Latest news

Focus on bifurcation lesions, LAAC compared to OAC in AF, ViV for AVR, assessing AR; a new classification for the BASILICA technique

Representative cases for computational fluid dynamics analysis of culotte

October 9, 2020

Antithrombotic drugs in bifurcation PCI

October 14, 2020

Left atrial appendage closure – ready for widespread clinical use?

October 14, 2020

This Week's JAA's: The TRI-REPAIR Study two-year outcomes, Percutaneous mitral valve leaflet repair...

October 13, 2020

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Better guidelines for bifurcation lesions?

Adrian P. Banning

October 9, 2020

Spyral, Popular-Tavi, Sort out IX, Solve TAVI, and more

(Released thanks to the support of Biotronik)

September 30, 2020

Valvular disease